NGEN NervGen Pharma Corp

$NGEN The muted response to this news is absolutely bizzare. Some people here have ben calling management inept while they are quietly but aggressively executing on their primary objective. It usally takes a phase 3 registrational trial 6-9 months to go from FDA alignment to actively recruting - NGEN management did it in 5.7 months. It can also take MANY MONTHS on average, especially in a CNS trial, to go from "actively recruiting" to "first patient dosed" ... they just accomplished that in 2 weeks... that is almost UNHEARD OF, check for yourself. The most important thing is that management is able to execute ahead of schedule... so when they say they will complete recruitment in H2 2027 and topline readout in H1 2028... I think they're going to beat that. We could be roughly a year from topline readout for a drug that addresses a massive unmet need, has zero competition and potential peak sales in the billions... INSANE UNDERVALUATION.

$NGEN Is there any other company even remotely close to NervGen's NVG-291? Because I've looked and they're only at animal studies. That's a decade or more behind Nervgen. And that is only if they have some promise. NVG-291 is already being proven effective. In humans. That is a major leap from rat studies. As anyone who follows pharma knows that rats often respond to treatments much easier/better than humans. The data gathered on NVG-291 alone is worth billions. The data will allow these peptide treatments to leapfrog years in advancements.

$NGEN If you want to talk value for money, please show me another Biotech that has started an FDA sanctioned and approved ph 3 design trial with multiple prestigious medical centers around North America! This design was built on the phenomenal results of their ph 2 trial, going after a largely unmet need/treatment in spinal cord injuries and potentially many other neuroreparative conditions. AND have a market cap of under $200 million???????? Exactly! I predict this little known tiny Biotech will make major waves in the next 12 to 18 months and will probably be bought out by some lucky BP!

$NGEN Nothing is going to happen until there is proof of a working drug that fills an unmet need. I believe the odds are good that NGEN has that with NVG-291. Look at phase 2 it's solid to say the least. Good things come to those who wait!

$NGEN I have that Yabushi guy blocked now, but saw the comments in your reshare and it's too funny, have to comment. The chart below shows some of the STRONG data produced from our phase 2. Do like I did, ask a mathematical model what the probability is that all of this just occured 'by chance'... the number I got just from picking three of these data points randomly was a 6 in a million chance or 0.000006 p value, lol. In other words, we know the drug is biologically active. So the purpose of the phase 3 is to ensure we're doing enough to eliminate 'statistical noise'. Going from a 20 person trial to a 150 person trial massively reduces the risk of statistical noise. By the way, ask your AI buddy why the FDA agreed to a trial design with 150 patients rather than 300 or 600+ (as is typical in CNS)... it is because the data from phase 2 was compelling enough that a much small would be sufficient to create a very high (95-99%) chance of statistical success.

$NGEN finally added. I have a very big position that has melted in value. So even buying a bit here seems to make sense to average down. I do believe they will succeed in their p3. The drug works, it’s not a placebo effect. Even small n, the gait analysis was statistically significant. That’s for me a clear sign of the drug at work, in conjunction with all the other evidence.

$NGEN 🏥 NervGen Pharma Corp. announced the first participant was dosed in the Phase 3 registrational RESTORE study evaluating NVG-291 in chronic cervical motor-incomplete spinal cord injury to potentially improve hand function and quality of life.

$NGEN leerink R&D Day Supports Confidence in RESTORE Study ● Bottom line: NervGen’s R&D Day was constructive, and we came away incrementally more positive on the rationale and design of the Phase 3 RESTORE study in traumatic spinal cord injury (tSCI), specifically more confidence in the Phase 3 primary endpoint. Management provided additional scientific context supporting NVG-291’s mechanism of action, clarified why modest improvements in hand function can meaningfully improve patients’ lives, and gave more detail on the GRASSP Quantitative Prehension (QtP) measure, which is the primary endpoint of RESTORE. We believe RESTORE is well-designed to capture NVG-291’s potential benefit, with an FDA-aligned endpoint, the same chronic cervical motor-incomplete population studied in Phase 2a CONNECT, rigorous GRASSP standardization, and close monitoring of at-home dosing. We believe gain in hand function is important, and with over 300K patients with tSCI in the US alone, the unmet need is real.

$NGEN Lots of biotechs have enthusiastic management teams. Far fewer have clinical-trial participants and their families becoming organised advocates, going to Capitol Hill and pushing regulators to recognise meaningful recovery.

$NGEN you have to be complete piece of shit to short this for nickel's and dimes when it could go up to 100$ a share in a year. How much of a tool do you have to be to wish the company that will help millions of people fails. Go back to scamming elderly people you broke bitch

$NGEN Investors, here are my best estimates and evidence-weighted working estimates, as well as PPS based off various P3 outcomes. Bring on the discussion! ⁠@biotechwinnersnews ⁠

$NGEN Nervgen has now registered 23 clinical trial sites faster than another of my biotechs registered 3 sites...

$NGEN The ”unless…accelerated approval” condition only became possible once P3 started. It’s been less than a week. There are many forms of advocacy happening that should at least speed up awareness/enrollment/completion if not beget some ”regulatory flexibility.” Educated patients across neuro indications are starting to demand progress. The MS community is 3X or more larger than SCI and they know about 291 and the results with ISP in animal models. Adding and waiting, even at the expense of other high-conviction positions. I don’t expect the wait to be that long. ymmv.

$NGEN don’t worry about the Market Making bros trolling the board like they are Warren Buffett - the move to NASDAQ has hurt the stock because more liquid providers means more trading desks trying to skim the market and also make prop trading profits - 10 cent moves don’t make a trend and the company is in its best fundamental position in its history

$NGEN my biggest concern is that Big Pharma will stay away from NGEN until it’s much further along and quite successful on its own. Big Pharma doesn’t like cures! They’re all about care and the recurring revenues that implies. But 🤷 That being said, as a chronic SCI I’m psyched looking forward to getting NVG-291 treatment.

$NGEN Well my 2 favorite Bios are getting shit kicked it seems......and yet nothing has changed.....NGEN just gets more and more undervalued, and IBRX(even with all of their good news) has some shorts to deal with. Still 2 of the most promising stocks in the Biotech world...one just needs to have the ability to hang on as good things are coming to both! IMO

$NGEN I don’t think I’ve ever seen so many trial participants go to the media to share their stories. Hopefully, with 75 patients in Phase 3, we’ll see a flood of similar testimonials.

$NGEN RESTORE is officially recruiting. Lutherville, Maryland appears to be the first site recruiting, and people on Reddit are already reporting that they have received emails about the study.

$NGEN Well that is just ridiculous and totally incorrect!!! What exactly are you smoking??? Their ph 1/2 data was incredibly strong and if they get close to replicating this data in the ph 3(and management feels that the efficacy may even be stronger in the Restore trial), this stock is going to rocket! "Raising awareness"?????? Remember the FDA supported this data and their ph 3 design and approval. So if you have something accurate to report or comment on, that would be greatly appreciated....but baseless useless posts like yours just don't make any sense...buh bye!!!!

$NGEN As of 4 October 2026, RESTORE has moved from planning/site-start-up into actual recruitment execution: On 29 September, the Phase 3 record changed from “Not Yet Recruiting” → “Recruiting.” At the 30 September R&D Day, Adam Rogers explicitly said NervGen had “officially begun screening patients following initial site activation this past week.” During Q&A he reinforced it: “We obviously just opened enrollment this week.” He said they expect “pretty robust recruitment” because of the large prevalent chronic-SCI population, broader geography and removal of the MEP eligibility hurdle that hampered CONNECT.